Page 5 - Multiple Sclerosis Ms News Today

The disease-modifying drug teriflunomide reduces the risk of developing clinical multiple sclerosis by 72% in radiologically isolated syndrome.

Catherine M. DiGiorgio, MD, MS, found herself at a crossroads: stay and work for a large corporation or open a solo practice?

Sandozs natalizumab-sztn injection (Tyruko) is on par with Biogens Tysabri (natalizumab) for treatment of relapsing forms of MS, the FDA said in approving the first biosimilar to treat MS.

Smoking has been linked to more rapid MS progression and greater disease severity but new data suggest oral tobacco use tied to slower disease progression.

Did you know that stress can have physical manifestations in unique areas of our bodies? On World Brain Day, Midday Online spoke to a psychologist to uncover ho

Initiating treatment within 6 months of the first symptoms of multiple sclerosis is linked to a 45% lower risk for disability years later.

Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.

The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.

Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.

"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.